Malignant Subtype of Cystosarcoma Phyllodes with Brain Metastases

Czech version

Authors: T. Büchler ¹; E. Voršilková ¹; F. Koukolík ²; H. Melínová ³; J. Abrahámová ¹
Authors‘ workplace: Onkologické oddělení, Fakultní Thomayerova nemocnice a 1. lékařská fakulta Univerzity Karlovy, Praha ¹; Oddělení patologie, Fakultní Thomayerova nemocnice, Praha ²; Radiodiagnostické oddělení, Fakultní Thomayerova nemocnice, Praha ³
Published in: Klin Onkol 2010; 23(6): 446-448
Category: Case Reports

Overview

Cystosarcoma phyllodes is an uncommon type of breast tumour. Benign, borderline, and malignant subtypes have been described. Central nervous system metastases of the malignant subtype of cystosarcoma phyllodes are rare and associated with poor prognosis. We report on a patient with malignant cystosarcoma phyllodes who developed metastatic disease six years after resection of the primary breast tumour. Partial regression of a brain metastasis was achieved using radiotherapy but the patient later died due to widespread metastatic disease which was uncontrollable by systemic chemotherapy. Because metastatic malignant cystosarcoma phyllodes are largely resistant to treatment, the most important objective is to provide optimal management of the primary tumour before dissemination occurs.

Keywords:
cystosarcoma phyllodes – chemotherapy – radiotherapy – brain neoplasms

Sources

1. Brown AP, Gaffney DK, Macdonald OK. Malignant Phyllodes Tumor of the Breast: Is Adjuvant Radiotherapy Necessary? In: Hayat MA (ed.). Methods of Cancer Diagnosis, Therapy, and Prognosis. Volume 1. Springer Netherlands 2008: 625– 635.

2. Burstein HJ, Harris JR, Morrow M. Malignant Tumors of the Breast. In: DeVita VT Jr, Lawrence TS, Rosenberg SA (eds). DeVita, Hellman, and Rosenberg‘s Cancer: Principles & Practice of Oncology. 8th Ed. Philadelphia, USA: Williams & Wilkins 2008: 1644.

3. Macdonald OK, Lee CM, Tward JD et al. Malignant phyllodes tumor of the female breast: association of primary therapy with cause– specific survival from the Surveillance, Epidemiology, and End Results (SEER) program. Cancer 2006; 107(9): 2127– 2133.

4. Asoglu O, Ugurlu MM, Blanchard K et al. Risk factors for recurrence and death after primary surgical treatment of malignant phyllodes tumors. Ann Surg Oncol 2004; 11(11): 1011– 1017.

5. Soumarová R, Seneklová Z, Horová H et al. Retrospective analysis of 25 women with malignant cystosarcoma phyllodes – treatment results. Arch Gynecol Obstet 2004; 269(4): 278– 281.

6. Hlavin ML, Kaminski HJ, Cohen M et al. Central nervous system complications of cystosarcoma phyllodes. Cancer 1993; 72(1): 126– 130.

7. Khan SA, Badve S. Phyllodes Tumors of the Breast. Current Treatment Options in Oncology 2001; 2(2): 139– 147.

8. Chaney AW, Pollack A, McNeese MD et al. Primary treatment of cystosarcoma phyllodes of the breast. Cancer 2000; 89(7): 1502– 1511.

9. Barth RJ Jr, Wells WA, Mitchell SE et al. A prospective, multi‑institutional study of adjuvant radiotherapy after resection of malignant phyllodes tumors. Ann Surg Oncol 2009; 16(8): 2288– 2294.